First Randomized Tri
First Randomized Trial of the Stellarex™ Drug-coated Balloon Presented at the Amputation Prevention Symposium
10 août 2016 17h58 HE | The Spectranetics Corporation
COLORADO SPRINGS, Colo., Aug. 10, 2016 (GLOBE NEWSWIRE) -- The Spectranetics Corporation (NASDAQ:SPNC) today announced that Professor Marianne Brodmann of Medical University Graz, Austria,...
Spectranetics Receiv
Spectranetics Receives CE Mark for AngioSculptX™
10 août 2016 09h00 HE | The Spectranetics Corporation
COLORADO SPRINGS, Colo., Aug. 10, 2016 (GLOBE NEWSWIRE) -- The Spectranetics Corporation (NASDAQ:SPNC) today announced receipt of CE marking for the AngioSculptX Drug-coated PTCA Scoring Balloon...
Spectranetics Report
Spectranetics Reports Second Quarter 2016 Revenue of $67.7 million
28 juil. 2016 16h01 HE | The Spectranetics Corporation
COLORADO SPRINGS, Colo., July 28, 2016 (GLOBE NEWSWIRE) -- The Spectranetics Corporation (NASDAQ:SPNC) today reported financial results for the three months ended June 30, 2016. ...
Federal Circuit Court Rules in Appeal
21 juil. 2016 13h20 HE | The Spectranetics Corporation
COLORADO SPRINGS, Colo., July 21, 2016 (GLOBE NEWSWIRE) -- The Spectranetics Corporation (NASDAQ:SPNC) today announced that the United States Court of Appeals for the Federal Circuit reversed in...
12-month Results of
12-month Results of the ILLUMENATE European Randomized Clinical Trial to be Presented at the Amputation Prevention Symposium
20 juil. 2016 09h00 HE | The Spectranetics Corporation
COLORADO SPRINGS, Colo., July 20, 2016 (GLOBE NEWSWIRE) -- The Spectranetics Corporation (NASDAQ:SPNC) today announced that Professor Marianne Brodmann of Medical University Graz, Austria, will...
Spectranetics to Host Second Quarter 2016 Conference Call on July 28, 2016
07 juil. 2016 09h00 HE | The Spectranetics Corporation
COLORADO SPRINGS, Colo., July 07, 2016 (GLOBE NEWSWIRE) -- The Spectranetics Corporation (Nasdaq:SPNC) today announced that the Company will release second quarter 2016 financial results after the...
Second Interim Analy
Second Interim Analysis on ILLUMENATE Global Study Presented on Spectranetics’ Stellarex drug-coated balloon at NCVH
01 juin 2016 16h00 HE | The Spectranetics Corporation
COLORADO SPRINGS, Colo., June 01, 2016 (GLOBE NEWSWIRE) -- The Spectranetics Corporation (NASDAQ:SPNC) today announced that Dr. Prakash Krishnan of Mount Sinai Medical Center, New York, NY...
Spectranetics to Pre
Spectranetics to Present at the UBS Global Healthcare Conference
11 mai 2016 16h00 HE | The Spectranetics Corporation
COLORADO SPRINGS, Colo., May 11, 2016 (GLOBE NEWSWIRE) -- The Spectranetics Corporation (NASDAQ:SPNC) today announced that Chief Financial Officer Stacy McMahan will be presenting at the UBS...
Spectranetics Achiev
Spectranetics Achieves First Quarter 2016 Revenue of $62.9 million
28 avr. 2016 16h00 HE | The Spectranetics Corporation
COLORADO SPRINGS, Colo., April 28, 2016 (GLOBE NEWSWIRE) -- The Spectranetics Corporation (NASDAQ:SPNC) today reported financial results for the three months ended March 31, 2016. ...
12-Month Interim ILL
12-Month Interim ILLUMENATE Global Study Data Presented on Spectranetics’ Stellarex drug-coated balloon at Charing Cross
26 avr. 2016 06h30 HE | The Spectranetics Corporation
COLORADO SPRINGS, Colo., April 26, 2016 (GLOBE NEWSWIRE) -- The Spectranetics Corporation (NASDAQ:SPNC) today announced that Professor Thomas Zeller presented 12-month interim data from the...